Press Room

IFPAC 2023

Start
Sunday, June 04, 2023 - 00:00
End
Wednesday, June 07, 2023 - 00:00
Location: Maryland, USA

Hovione is present at the International Forum Process Analytical Technology (IFPAC), a forum that brings the latest trends and real-life applications in the fields of Quality by Design, Process Analytical Technology, Emerging Technologies, Quality Metrics, Continuous Manufacturing and Process Control applications for the pharmaceutical industry, biotechnology, generic, chemical and related industries.

 

HOVIONE PRESENTATIONS

Hovione experts share their knowledge at IFPAC® - 37th International Forum Process Analytical Technology
June 4-7, 2023 | North Bethesda, Maryland (Washington D.C.)

 

June 6: Grand Ballroom G | 4:50 PM - 5:15 PM
Part of session: Recent Developments to Realizing Continuous Manufacturing
Presentation Title: Use of Statistical Process Control to drive process improvements in continuous manufacturing
Primary presenter: Fernando Barros

 

June 7: Grand Ballroom C | 7:50 AM - 12:00 PM
Session: Defining Incentives and Business Cases for PAT - Defining the Boundaries between Batch & Continuous Manufacturing
Chair: Anthony Tantuccio

 

June 7: Glen Echo Conference Room | 11:10 AM - 11:35 AM
Part of session: Enhanced Analytical Approaches & Modeling for Process Optimization
Presentation Title: A template for investigating NIR spectroscopy-based deviations
Primary presenter: Fernando Barros

 

June 7: White Flint Amphitheatre | 1:05 PM - 5:40 PM
Part of session: Continued Process Verification (CPV) - Practices, Challenges and Opportunities
Presentation Title: Enhance Spray Drying CPV using MVDA
Primary presenter: Tiago Porfirio

 

One approach to enhancing Continued process verification (CPV) is through the use of multivariate data analysis (MVDA), which allows for the identification of correlations and patterns between process parameters and product quality attributes. MVDA involves the analysis of multiple variables simultaneously, allowing for a comprehensive understanding of the process and its impact on product quality. By analyzing data from multiple sources, including automated control systems and quality control testing, MVDA can help identify the critical process parameters (CPPs) and critical quality attributes (CQAs) that are most strongly correlated with product quality. This approach can significantly improve process efficiency and product quality while reducing the risk of product failure, reprocessing and rework. Moreover, MVDA provide insights into potential causes for process deviations, facilitating the development of corrective actions. This proactive approach to CPV helps to ensure that the process remains within established control limits, minimizing the risk of non-compliance. This work will show how the integration of MVDA into CPV in a spray drying process can significantly enhance process control and product quality by leveraging multivariate data analysis.
 

 

 

Meet our experts. Let’s discuss your project together.

 

 

Find more about IFPAC.

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026